Lee Seok, Kim Yoo-Jin, Eom Ki-Seong, Min Chang-Ki, Kim Hee-Je, Cho Seok-Goo, Lee Jong-Wook, Min Woo-Sung, Kim Chun-Choo
Catholic Hematopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Haematologica. 2006 May;91(5):671-4. Epub 2006 Apr 19.
Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction. At a median follow-up of 44 months, nine relapses had occurred. The 5-year probabilities of relapse and disease-free survival were 17.3+/-5.4% and 81.5+/-5.4%, respectively. A MRD level of >10-3 after first consolidation was the most powerful predictor of relapse (85.7+/-13.2% versus 7.3+/-4.1%, p<0.001) and disease-free survival (14.3+/-13.2% versus 91.2%+/-4.3%, p<0.001). Prospective MRD monitoring may allow us to identify subgroups of patients at high risk of relapse earlier during treatment.
通过实时定量聚合酶链反应研究了70例急性早幼粒细胞白血病成人患者，以明确微小残留病（MRD）水平及动力学在其整个治疗过程中的意义。中位随访44个月时，发生了9例复发。5年复发概率和无病生存率分别为17.3±5.4%和81.5±5.4%。首次巩固治疗后MRD水平>10-3是复发（85.7±13.2%对7.3±4.1%，p<0.001）和无病生存（14.3±13.2%对91.2%±4.3%，p<0.001）的最有力预测因素。前瞻性MRD监测可能使我们在治疗期间更早地识别出复发高危患者亚组。
